Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Geneora Pharma (Shijiazhuang) Co. Ltd. holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data indicates there is 1 pending office action currently active. This action represents the total volume of active prosecution for the company's pharmaceutical technologies. For a practitioner, this indicates a focused stage of engagement where a single application is the primary focus of legal efforts at the USPTO.
The examination process involves a distinct examiner and a single art unit. This concentration points to a specific technical focus for the company's filings within the USPTO's biotechnology divisions. MAHLUM, JONATHAN DAVIS is the busiest examiner assigned to the portfolio. The use of a single art unit allows for a consistent application of examination standards and technical review to the company's pharmaceutical innovations.
MAHLUM, JONATHAN DAVIS is handling 1 busiest examiner pending office action. As the total number of pending office actions is 1, MAHLUM, JONATHAN DAVIS manages the entire active workload. Practitioners should focus on the specific examination style of MAHLUM, JONATHAN DAVIS and the standards of the art unit to advance the company's patenting goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAHLUM, JONATHAN DAVIS | 1 | 51.4% | +25.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005952 | 5-HT2A RECEPTOR INHIBITOR OR INVERSE AGONIST, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | MAHLUM, JONATHAN DAVIS | 11d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18005952 | 5-HT2A RECEPTOR INHIBITOR OR INVERSE AGONIST, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 11d overdue | Pending | Jan 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial